The anti-yellow fever virus activity of ribavirin is independent of error-prone replication

Molecular Pharmacology

Volumn 69, Issue 4, 2006, Pages 1461-1467

  Leyssen, Pieter ^a   De Clercq, Erik ^a   Neyts, Johan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYL 4 IMIDAZOLECARBOXAMIDE 1 RIBOSIDE; GUANOSINE TRIPHOSPHATE; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; RIBAVIRIN; VIRUS RNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DISASTER; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FLAVIVIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PARAMYXOVIRUS; PRIORITY JOURNAL; VIRUS CULTURE; VIRUS REPLICATION; YELLOW FEVER FLAVIVIRUS;

ANIMALS; ANTIVIRAL AGENTS; BASE SEQUENCE; CERCOPITHECUS AETHIOPS; DNA PRIMERS; RIBAVIRIN; SERIAL PASSAGE; VERO CELLS; VIRUS REPLICATION; YELLOW FEVER VIRUS;

EID: 33645102511     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.105.020057     Document Type: Article

References (37)

1. Airaksinen A, Pariente N, Menendez-Arias L, and Domingo E (2003) Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology 311:339-349.
2. Asahina Y, Izumi N, Enomoto N, Uchihara M, Kurosaki M, Onuki Y, Nishimura Y, Ueda K, Tsuchiya K, Nakanishi H, et al. (2005) Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol 43:623-629.
3. Balzarini J, Karlsson A, Wang L, Bohman C, Horska K, Votruba I, Fridland A, Van Aerschot A, Herdewijn P, and De Clercq E (1993) Eicar (5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis. J Biol Chem 268:24591-24598.
4. Balzarini J, Stet L, Matsuda A, Wiebe L, Knauss E, and De Clercq E (1998) Metabolism of EICAR (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide), a potent inhibitor of inosinate dehydrogenase. Adv Exp Med Biol 431:723-728.
5. Benarroch D, Egloff MP, Mulard L, Guerreiro C, Romette JL, and Canard B (2004) A structural basis for the inhibition of the NS5 dengue virus mRNA 2′-O-methyltransferase domain by ribavirin 5′-triphosphate. J Biol Chem 279:35638-35643.
6. Bougie I and Bisaillon M (2004) The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme. J Biol Chem 279:22124-22130.
7. Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV, and Chung RT (2002) Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol 76:8505-8517.
8. Crotty S, Cameron CE, and Andino R (2001) RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA 98:6895-6900.
9. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, and Cameron CE (2000) The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 6:1375-1379.
10. Day CW, Smee DF, Julander JG, Yamshchikov VF, Sidwell RW, and Morrey JD (2005) Error-prone replication of West Nile virus caused by ribavirin. Antiviral Res 67:38-45.
11. Domingo E, Escarmis C, Sevilla N, Moya A, Elena SF, Quer J, Novella IS, and Holland JJ (1996) Basic concepts in RNA virus evolution. FASEB J 10:859-864.
12. Drake JW, Charlesworth B, Charlesworth D, and Crow JF (1998) Rates of spontaneous mutation. Genetics 148:1667-1686.
13. Eriksson B, Helgstrand E, Johansson NG, Larsson A, Misiorny A, Noren JO, Philipson L, Stenberg K, Stening G, Stridh S, et al. (1977) Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother 11:946-951.
14. Goswami BB, Borek E, Sharma OK, Fujitaki J, and Smith RA (1979) The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. Biochem Biophys Res Commun 89:830-836.
15. Lanford RE, Chavez D, Guerra B, Lau JY, Hong Z, Brasky KM, and Beames B (2001) Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J Virol 75:8074-8081.
16. Leyssen P, Balzarini J, De Clercq E, and Neyts J (2005) The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 79:1943-1947.
17. Leyssen P, De Clercq E, and Neyts J (2000) Perspectives for the treatment of infections with Flaviviridae. Clin Microbiol Rev 13:67-82.
18. Lutchman GA, Danehower S, Park Y, Ward C, Liang JT, and Hoofnagle JH (2004) Mutation rate of hepatitis C virus in patients during ribavirin monotherapy. Hepatology 40 (Suppl 1):385A.
19. Maag D, Castro C, Hong Z, and Cameron CE (2001) Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 276:46094-46098.
20. Malinoski F and Stollar V (1981) Inhibitors of IMP dehydrogenase prevent Sindbis virus replication and reduce GTP levels in Aedes albopictus cells. Virology 110:281-289.
21. Neyts J, Meerbach A, McKenna P, and De Clercq E (1996) Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections. Antiviral Res 30:125-132.
22. Pariente N, Airaksinen A, and Domingo E (2003) Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J Virol 77:7131-7138.
23. Pawlotsky JM, Brillet R, Hezode C, and Dhumeaux D (2004) Is ribavirin antiviral effect in humans mediated b mutagenic properties resulting in error catastrophe? J Hepatol 40 (Suppl 1):23.
24. Pawlotsky JM, Chevaliez S, Brillet R, Hezode C, and Dhumeaux D (2005) Assessment of ribavirin mutagenic properties in vivo and the influence of interferon alpha-induced reduction of hepatitis C virus load upon therapy, in Proceedings of the 12th International Symposium on Hepatitis C Virus and Related Viruses; 2005 October 2-6; Montréal, QC, Canada. Abstract 0-14.
25. Perelson AS and Ribeiro RM (2005) Mutagenic effects of ribavirin in vivo. J Hepatol 43:553-555.
26. Pfeiffer JK and Kirkegaard K (2003) A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci USA 100:7289-7294.
27. Pugachev KV, Guirakhoo F, Ocran SW, Mitchell F, Parsons M, Penal C, Girakhoo S, Pougatcheva SO, Arroyo J, Trent DW, et al. (2004) High fidelity of yellow fever virus RNA polymerase. J Virol 78:1032-1038.
28. Rankin JT Jr, Eppes SB, Antczak JB, and Joklik WK (1989) Studies on the mechanism of the antiviral activity of ribavirin against reovirus. Virology 168:147-158.
29. Reed LJ and Muench H (1938) A simple method of estimating 50 per cent end-points. Am J Hyg 27:496-497.
30. Ruiz-Jarabo CM, Ly C, Domingo E, and de la Torre JC (2003) Lethal mutagenesis of the prototypic arenavirus lymphocytic choriomeningitis virus (LCMV). Virology 308:37-47.
31. Scheidel LM, Durbin RK, and Stollar V (1987) Sindbis virus mutants resistant to mycophenolic acid and ribavirin. Virology 158:1-7.
32. Scheidel LM and Stollar V (1991) Mutations that confer resistance to mycophenolic acid and ribavirin on Sindbis virus map to the nonstructural protein nsP1. Virology 181:490-499.
33. Schinkel J, de Jong MD, Bruning B, van Hoek B, Spaan WJ, and Kroes AC (2003) The potentiating effect of ribavirin on interferon in the treatment of hepatitis C: lack of evidence for ribavirin-induced viral mutagenesis. Antivir Ther 8:535-540.
34. Severson WE, Schmaljohn CS, Javadian A, and Jonsson CB (2003) Ribavirin causes error catastrophe during Hantaan virus replication. J Virol 77:481-488.
35. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, and Robins RK (1972) Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1, 2,4-triazole-3-carboxamide. Science (Wash DC) 177:705-706.
36. Streeter DG, Witkowski JT, Khare GP, Sidwell RW, Bauer RJ, Robins RK, and Simon LN (1973) Mechanism of action of 1-β-D-ribofuranosyl-1,2,4-triazole- 3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc Natl Acad Sci USA 70:1174-1178.
37. Witkowski JT, Robins RK, Sidwell RW, and Simon LN (1972) Design, synthesis and broad spectrum antiviral activity of 1-β-D-ribofuranosyl-1,2, 4-triazole-3-carboxamide and related nucleosides. J Med Chem 15:1150-1154.